Document Detail


Antipsychotics and abnormal liver function tests: systematic review.
MedLine Citation:
PMID:  22986798     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: Systematic assessment of the prevalence and pattern of liver function test (LFT) abnormalities associated with regular antipsychotics in adult humans and consideration of management of such abnormalities.
DATA SOURCES: Systematic search identifying cohort, cross-sectional or case studies/series, reporting LFT abnormalities in patients receiving regular antipsychotics. EMBASE, PsychINFO, and MEDLINE were searched for studies in English from record onset.
STUDY SELECTION: Abstracts were independently screened for eligibility by 2 researchers. Ineligible studies included those that did not report LFT reference ranges, those that studied fewer than 10 patients on a given antipsychotic, and those studying children.
DATA EXTRACTION: Key variables in group studies were extracted. Case studies/series were examined for patient outcome.
DATA SYNTHESIS: Ten group studies and 91 case studies/series were eligible, although quality was poor. All groups receiving regular antipsychotics had a prevalence of LFT abnormalities greater than chance. The median percentage of patients with any abnormal LFT on any antipsychotic was 32%, with a range of 5% to 78%. The median percentage of patients with clinically significant elevations was 4%, with a range of 0% to 15%. Transaminases were most commonly elevated. Abnormalities were generally asymptomatic, arose within 6 weeks, and were either stably persistent or resolved with continued treatment. Case reports suggested that antipsychotics can be associated with severe hepatitis, fatal in a small minority of cases. Chlorpromazine is most commonly associated with acute liver injury.
CONCLUSIONS: The LFT abnormalities in patients receiving regular antipsychotics are common but generally mild and transient. Very rarely, a severe or fatal hepatic injury can emerge.
Authors:
Katie F M Marwick; Mark Taylor; Simon W Walker
Related Documents :
23227078 - Clinical features according to the frequency of acute exacerbation in copd.
23373748 - Higher degree of left atrial structural remodeling in patients with atrial fibrillation...
23599328 - Reduction in blood glutathione levels occurs similarly in patients with primary-open an...
23358608 - Serum extracellular secreted antagonists of the canonical wnt/β-catenin signaling path...
12890198 - Long-term dermoscopic follow-up of melanocytic naevi: clinical outcome and patient comp...
9430858 - Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  35     ISSN:  1537-162X     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  244-53     Citation Subset:  IM    
Affiliation:
*Division of Psychiatry, Kennedy Tower, and †Psychiatry, Royal Edinburgh Hospital; and ‡Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Co-occurring psychotic and addictive disorders: neurobiology and diagnosis.
Next Document:  Iatrogenic botulism after the therapeutic use of botulinum toxin-a: a case report and review of the...